why do most analyst say gold to be, page-7

general biotech stock picks for 2006 BTA-Relenza royalties and winning suit could send share over 3.
PTD-Steady growth over 2
SRX- Most undervalued as already is profitable,has small float, and yesterday got big revenue boost by having Aussie Health Ministry approve its 14,000 per treatment product- Sir Spheres. Also had previos bid of $4.85 which was rejected 2 years ago, and now new bid could emerge as Pfizer and Sanofi are partnering with Sirtex.